Med Discovery SA

Med Discovery SA ( Med Discovery ), a privately held biotechnology company involved in development of therapeutic proteins for the treatment of prostate, bladder, and ovarian cancer diseases. The company offers RFPS system for applications which includes characterization of substrate in a protein context, study of kinetic cleavage, and determination of cleavage site and also human recombinant protease substrate proteins for biochemical in vitro assays. In addition, it also provides protease research, in-vitro screening, and in-vivo screening services. Recently , the company has out-licensed all rights for dermatology of its kallikrein inhibitor MDPK67b to Dermadis SA. Med Discovery is headquartered in Geneva, Switzerland.

Street: 
Chemin des Aulx 16
City: 
Geneva
Postcode: 
1228
Federal State : 
Switzerland
WebSite: 
info@med-discovery
Fax: 
41-22-7061753

Company Index Score

Current Index Score Historical Index Score
  • Med Discovery SA currently scores 50 % in the index.
  • Med Discovery SA is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Med Discovery SA is currently ranked 1 out of 4535 companies. This is in the top 0.022 % percent of Pharmaceutical companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets